Syracuse

Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines.

Archive ouverte

Ploquin, Aurélie | Szécsi, Judit | Mathieu, Cyrille | Guillaume, Vanessa | Barateau, Véronique | Ong, Kien Chai | Wong, Kum Thong | François-Loïc, Cosset | Horvat, Branka | Salvetti, Anna

Edité par CCSD ; Oxford University Press -

International audience. Nipah virus (NiV) and Hendra virus (HeV) are closely related, recently emerged paramyxoviruses that are capable of causing considerable morbidity and mortality in several mammalian species, including humans. Henipavirus-specific vaccines are still commercially unavailable, and development of novel antiviral strategies to prevent lethal infections due to henipaviruses is highly desirable. Here we describe the development of adeno-associated virus (AAV) vaccines expressing the NiV G protein. Characterization of these vaccines in mice demonstrated that a single intramuscular AAV injection was sufficient to induce a potent and long-lasting antibody response. Translational studies in hamsters further demonstrated that all vaccinated animals were protected against lethal challenge with NiV. In addition, this vaccine induced a cross-protective immune response that was able to protect 50% of the animals against a challenge by HeV. This study presents a new efficient vaccination strategy against henipaviruses and opens novel perspectives on the use of AAV vectors as vaccines against emergent diseases.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion